ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2alpha Antagonist, for the ...
GENEVA, July 28, 2016 (GLOBE NEWSWIRE) -- ObsEva, a biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics from conception to birth, announced today the initiation of a Phase 1 clinical program of OBE022, a novel, …